ubidecarenone IV (BPM 31510 IV) / BPGbio 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   85 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ubidecarenone IV (BPM 31510 IV) / BPGbio
2017-001470-42: A Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection with Gemcitabine in Patients with Advanced Pancreatic Cancer

Not yet recruiting
2
80
Europe
BPM31510-V 4% nanosuspension, Any approved Gemcitabine Marketed Trade Name approved in UK, BPM31510, Suspension for injection, Powder for solution for infusion, Any approved Gemcitabine Marketed Trade Name approved in UK
BERG, LLC, BERG, LLC
Advanced Pancreatic Cancer, Advanced Pancreatic Cancer, Diseases [C] - Digestive System Diseases [C06]
 
 
BPM31510IV-11, NCT04752813: A Study of BPM31510 with Vitamin K1 in Subjects with Newly Diagnosed Glioblastoma (GB)

Recruiting
2
50
US
BPM31510, Vitamin K1, Temozolomide (TMZ), Radiation
BPGbio, BPGbio
Glioblastoma, Glioblastoma Multiforme
02/25
12/25

Download Options